马显才研究员
教育经历
2010.08-2014.06，中山大学，生物科学，本科
2014.07-2019.06，中山大学，微生物学，博士研究生
工作经历
2019.07-2021.10，中山大学中山医学院，博士后
2022.01-至今，广州国家实验室，研究员
2022.10-至今，广州医科大学附属第一医院，特聘教授（兼职）
研究简介
马显才研究员专注于冠状病毒与宿主互作分子的机制研究。并以机制为导向开展抗病毒干预手段（靶向药物与纳米疫苗）的应用基础研究。在冠状病毒纳米颗粒疫苗研究、抗冠状病毒药物研究和HIV-1潜伏感染机制研究中取得了系列学术成绩。研究成果发表在Immunity、Signal Transduction and Targeted Therapy、EMBO Journal、Cellular & Molecular Immunology、eLife、EMBO Reports、mBio等国际学术期刊上。近五年在国际期刊发表高水平研究论文30余篇，其中通讯/第一作者论文17篇，4篇IF＞10，总引用次数1800余次。授权抗病毒药物发明专利1项、纳米颗粒疫苗专利4项。主持国家自然科学基金、“十三五”国家科技重大专项子课题、广东省自然科学基金等基金项目11项。担任中国疫苗行业协会疫苗基础研究专业委员会委员、广东省免疫学会青年学者工作委员会委员、以及广东省呼吸与健康学会疫苗专委会常务委员。
人才头衔与荣誉奖励
1. 国家重大人才项目青年拔尖人才
2. 广东省自然杰出青年科学基金
3. 博士后创新人才支持计划（博新计划）入选者
代表性成果
1. Ma, Xiancai#; Zou, Fan#; Yu, Fei#; Li, Rong#; Yuan, Yaochang#; Zhang, Yiwen#; Zhang, Xiantao; Deng, Jieyi; Chen, Tao; Song, Zheng; Qiao, Yidan; Zhan, Yikang; Liu, Jun; Zhang, Junsong; Zhang, Xu; Peng, Zhilin; Li, Yuzhuang; Lin, Yingtong; Liang, Liting; Wang, Guanwen; Chen, Yingshi; Chen, Qier; Pan, Ting; He, Xin; Zhang, Hui*. 2020. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity. 53(6): 1315-1330.e9
2. Ma, Xiancai#; Chen, Tao; Peng, Zhilin; Wang, Ziwen; Liu, Jun; Yang, Tao; Wu, Liyang; Liu, Guangyan; Zhou, Mo; Tong, Muye; Guan, Yuanjun; Zhang, Xu; Lin, Yingtong; Tang, Xiaoping; Li, Linghua; Tang, Zhonghui; Pan, Ting; Zhang, Hui*. 2021. Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodies. The EMBO Journal. 19(2)
3. Wu, Liyang#; Pan, Ting#; Zhou, Mo; Chen, Tao; Wu, Shiyu; Lv, Xi; Liu, Jun; Yu, Fei; Guan, Yuanjun; Liu, Bingfeng; Zhang, Wanying; Deng, Xiaohui; Chen, Qianyu; Liang, Anqi; Lin, Yingtong; Wang, Lilin; Tang, Xiaoping; Cai, Weiping; Li, Linghua; He, Xin; Zhang, Hui*; Ma, Xiancai*. 2022. CBX4 contributes to HIV-1 latency by forming phase-separated nuclear bodies and SUMOylating EZH2. EMBO Reports. 23(7)
4. Ma, Xiancai#; Yang, Tao; Luo, Yuewen; Wu, Liyang; Jiang, Yawen; Song, Zheng; Pan, Ting; Liu, Bingfeng; Liu, Guangyan; Liu, Jun; Yu, Fei; He, Zhangping; Zhang, Wanying; Yang, Jinyu; Liang, Liting; Guan, Yuanjun; Zhang, Xu; Li, Linghua; Cai, Weiping; Tang, Xiaoping; Gao, Song; Deng, Kai; Zhang, Hui*. 2019. TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb. eLife. 8: e42426
5. Yu, Fei#; Liu, Xiaoqing#; Ou, Hailan; Li, Xinyu; Liu, Ruxin; Lv, Xi; Xiao, Shiqi; Hu, Meilin; Liang, Taizhen; Chen, Tao; Wei, Xuepeng; Zhang, Zhenglai; Liu, Sen; Liu, Han; Zhu, Yiqiang; Liu, Guangyan; Tu, Tianyong; Li, Peiwen; Zhang, Hui; Pan, Ting; Ma, Xiancai*. 2024. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2. mBio. 15(8): e0108824
6. Chen, Tao#; Deng, Jieyi; Zhang, Yongli; Liu, Bingfeng; Liu, Ruxin; Zhu, Yiqiang; Zhou, Mo; Lin, Yingtong; Xia, Baijin; Lin, Keming; Ma, Xiancai*; Zhang, Hui*. 2024. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments. Molecular Cancer. 23(1): 53
7. Lv, Xi#; Chen, Ran; Liang, Taizhen; Peng, Haojie; Fang, Qiannan; Xiao, Shiqi; Liu, Sen; Hu, Meilin; Yu, Fei; Cao, Lixue; Zhang, Yiwen; Pan, Ting; Xi, Zhihui; Ding, Yao; Feng, Linyuan; Zeng, Tao; Huang, Wenjing; Zhang, Hui*; Ma, Xiancai*. 2024. NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity. mBio. 15(3)
8. Yu, Fei#; Pan, Ting#; Huang, Feng#; Ying, Ruosu; Liu, Jun; Fan, Huimin; Zhang, Junsong; Liu, Weiwei; Lin, Yingtong; Yuan, Yaochang; Yang, Tao; Li, Rong; Zhang, Xu; Lv, Xi; Chen, Qianyu; Liang, Anqi; Zou, Fan; Liu, Bingfeng; Hu, Fengyu; Tang, Xiaoping; Li, Linghua; Deng, Kai; He, Xin; Zhang, Hui; Zhang, Yiwen; Ma, Xiancai*. 2022. Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L. Frontiers in Microbiology. 13: 884034
9. Li, Rong#; Ma, Xiancai#; Deng, Jieyi; Chen, Qier; Liu, Weiwei; Peng, Zhilin; Qiao, Yidan; Lin, Yingtong; He, Xin*; Zhang, Hui*. 2021. Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. Cellular and Molecular Immunology. 18(4): 1058-1060
10. Pan, Ting#; Chen, Ran#; He, Xin#; Yuan, Yaochang#; Deng, Xiaohui; Li, Rong; Yan, Haiping; Yan, Shumei; Liu, Jun; Zhang, Yiwen; Zhang, Xiantao; Yu, Fei; Zhou, Mo; Ke, Changwen; Ma, Xiancai*; Zhang, Hui*. 2021. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduction and Targeted Therapy. 6: 420
2010.08-2014.06，中山大学，生物科学，本科
2014.07-2019.06，中山大学，微生物学，博士研究生
工作经历
2019.07-2021.10，中山大学中山医学院，博士后
2022.01-至今，广州国家实验室，研究员
2022.10-至今，广州医科大学附属第一医院，特聘教授（兼职）
研究简介
马显才研究员专注于冠状病毒与宿主互作分子的机制研究。并以机制为导向开展抗病毒干预手段（靶向药物与纳米疫苗）的应用基础研究。在冠状病毒纳米颗粒疫苗研究、抗冠状病毒药物研究和HIV-1潜伏感染机制研究中取得了系列学术成绩。研究成果发表在Immunity、Signal Transduction and Targeted Therapy、EMBO Journal、Cellular & Molecular Immunology、eLife、EMBO Reports、mBio等国际学术期刊上。近五年在国际期刊发表高水平研究论文30余篇，其中通讯/第一作者论文17篇，4篇IF＞10，总引用次数1800余次。授权抗病毒药物发明专利1项、纳米颗粒疫苗专利4项。主持国家自然科学基金、“十三五”国家科技重大专项子课题、广东省自然科学基金等基金项目11项。担任中国疫苗行业协会疫苗基础研究专业委员会委员、广东省免疫学会青年学者工作委员会委员、以及广东省呼吸与健康学会疫苗专委会常务委员。
人才头衔与荣誉奖励
1. 国家重大人才项目青年拔尖人才
2. 广东省自然杰出青年科学基金
3. 博士后创新人才支持计划（博新计划）入选者
代表性成果
1. Ma, Xiancai#; Zou, Fan#; Yu, Fei#; Li, Rong#; Yuan, Yaochang#; Zhang, Yiwen#; Zhang, Xiantao; Deng, Jieyi; Chen, Tao; Song, Zheng; Qiao, Yidan; Zhan, Yikang; Liu, Jun; Zhang, Junsong; Zhang, Xu; Peng, Zhilin; Li, Yuzhuang; Lin, Yingtong; Liang, Liting; Wang, Guanwen; Chen, Yingshi; Chen, Qier; Pan, Ting; He, Xin; Zhang, Hui*. 2020. Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses. Immunity. 53(6): 1315-1330.e9
2. Ma, Xiancai#; Chen, Tao; Peng, Zhilin; Wang, Ziwen; Liu, Jun; Yang, Tao; Wu, Liyang; Liu, Guangyan; Zhou, Mo; Tong, Muye; Guan, Yuanjun; Zhang, Xu; Lin, Yingtong; Tang, Xiaoping; Li, Linghua; Tang, Zhonghui; Pan, Ting; Zhang, Hui*. 2021. Histone chaperone CAF-1 promotes HIV-1 latency by leading the formation of phase-separated suppressive nuclear bodies. The EMBO Journal. 19(2)
3. Wu, Liyang#; Pan, Ting#; Zhou, Mo; Chen, Tao; Wu, Shiyu; Lv, Xi; Liu, Jun; Yu, Fei; Guan, Yuanjun; Liu, Bingfeng; Zhang, Wanying; Deng, Xiaohui; Chen, Qianyu; Liang, Anqi; Lin, Yingtong; Wang, Lilin; Tang, Xiaoping; Cai, Weiping; Li, Linghua; He, Xin; Zhang, Hui*; Ma, Xiancai*. 2022. CBX4 contributes to HIV-1 latency by forming phase-separated nuclear bodies and SUMOylating EZH2. EMBO Reports. 23(7)
4. Ma, Xiancai#; Yang, Tao; Luo, Yuewen; Wu, Liyang; Jiang, Yawen; Song, Zheng; Pan, Ting; Liu, Bingfeng; Liu, Guangyan; Liu, Jun; Yu, Fei; He, Zhangping; Zhang, Wanying; Yang, Jinyu; Liang, Liting; Guan, Yuanjun; Zhang, Xu; Li, Linghua; Cai, Weiping; Tang, Xiaoping; Gao, Song; Deng, Kai; Zhang, Hui*. 2019. TRIM28 promotes HIV-1 latency by SUMOylating CDK9 and inhibiting P-TEFb. eLife. 8: e42426
5. Yu, Fei#; Liu, Xiaoqing#; Ou, Hailan; Li, Xinyu; Liu, Ruxin; Lv, Xi; Xiao, Shiqi; Hu, Meilin; Liang, Taizhen; Chen, Tao; Wei, Xuepeng; Zhang, Zhenglai; Liu, Sen; Liu, Han; Zhu, Yiqiang; Liu, Guangyan; Tu, Tianyong; Li, Peiwen; Zhang, Hui; Pan, Ting; Ma, Xiancai*. 2024. The histamine receptor H1 acts as an alternative receptor for SARS-CoV-2. mBio. 15(8): e0108824
6. Chen, Tao#; Deng, Jieyi; Zhang, Yongli; Liu, Bingfeng; Liu, Ruxin; Zhu, Yiqiang; Zhou, Mo; Lin, Yingtong; Xia, Baijin; Lin, Keming; Ma, Xiancai*; Zhang, Hui*. 2024. The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments. Molecular Cancer. 23(1): 53
7. Lv, Xi#; Chen, Ran; Liang, Taizhen; Peng, Haojie; Fang, Qiannan; Xiao, Shiqi; Liu, Sen; Hu, Meilin; Yu, Fei; Cao, Lixue; Zhang, Yiwen; Pan, Ting; Xi, Zhihui; Ding, Yao; Feng, Linyuan; Zeng, Tao; Huang, Wenjing; Zhang, Hui*; Ma, Xiancai*. 2024. NSP6 inhibits the production of ACE2-containing exosomes to promote SARS-CoV-2 infectivity. mBio. 15(3)
8. Yu, Fei#; Pan, Ting#; Huang, Feng#; Ying, Ruosu; Liu, Jun; Fan, Huimin; Zhang, Junsong; Liu, Weiwei; Lin, Yingtong; Yuan, Yaochang; Yang, Tao; Li, Rong; Zhang, Xu; Lv, Xi; Chen, Qianyu; Liang, Anqi; Zou, Fan; Liu, Bingfeng; Hu, Fengyu; Tang, Xiaoping; Li, Linghua; Deng, Kai; He, Xin; Zhang, Hui; Zhang, Yiwen; Ma, Xiancai*. 2022. Glycopeptide Antibiotic Teicoplanin Inhibits Cell Entry of SARS-CoV-2 by Suppressing the Proteolytic Activity of Cathepsin L. Frontiers in Microbiology. 13: 884034
9. Li, Rong#; Ma, Xiancai#; Deng, Jieyi; Chen, Qier; Liu, Weiwei; Peng, Zhilin; Qiao, Yidan; Lin, Yingtong; He, Xin*; Zhang, Hui*. 2021. Differential efficiencies to neutralize the novel mutants B.1.1.7 and 501Y.V2 by collected sera from convalescent COVID-19 patients and RBD nanoparticle-vaccinated rhesus macaques. Cellular and Molecular Immunology. 18(4): 1058-1060
10. Pan, Ting#; Chen, Ran#; He, Xin#; Yuan, Yaochang#; Deng, Xiaohui; Li, Rong; Yan, Haiping; Yan, Shumei; Liu, Jun; Zhang, Yiwen; Zhang, Xiantao; Yu, Fei; Zhou, Mo; Ke, Changwen; Ma, Xiancai*; Zhang, Hui*. 2021. Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route. Signal Transduction and Targeted Therapy. 6: 420